| dbo:abstract
|
- Voxelotor ist ein Arzneistoff zur Behandlung einer Blutarmut (hämolytische Anämie) aufgrund von Sichelzellkrankheit. Unter dem Handelsnamen Oxbryta (Hersteller: ) wurde er im November 2019 in den USA und im Februar 2022 in der EU zugelassen. Voxelotor ist oral anwendbar. (de)
- Voxelotor, sold under the brand name Oxbryta, is a medication used for the treatment of sickle cell disease. Developed by , voxelotor is the first hemoglobin oxygen-affinity modulator. Voxelotor has been shown to have disease-modifying potential by increasing hemoglobin levels and decreasing hemolysis indicators in sickle cell patients. It has a safe profile in sickle cell patients and healthy volunteers, without any dose-limiting toxicity. In November 2019, voxelotor received accelerated approval in the United States for the treatment of sickle cell disease (SCD) for those twelve years of age and older. The U.S. Food and Drug Administration (FDA) considers it to be a first-in-class medication. In December 2021, voxelotor received accelerated approval in the United States for the treatment of sickle cell disease (SCD) for those aged four to eleven years. (en)
- Вокселотор (Voxelotor, Оксбрита / Oxbryta) — лекарственный препарат для лечения серповидноклеточной анемии. В ноябре 2019 года Food and Drug Administration США в ускоренном режиме одобрило препарат компании . (ru)
|
| dbo:alternativeName
| |
| dbo:casNumber
| |
| dbo:chEMBL
| |
| dbo:drugbank
| |
| dbo:fdaUniiCode
| |
| dbo:kegg
| |
| dbo:medlinePlus
| |
| dbo:pubchem
| |
| dbo:thumbnail
| |
| dbo:wikiPageExternalLink
| |
| dbo:wikiPageID
| |
| dbo:wikiPageLength
|
- 11861 (xsd:nonNegativeInteger)
|
| dbo:wikiPageRevisionID
| |
| dbo:wikiPageWikiLink
| |
| dbp:atcPrefix
| |
| dbp:atcSuffix
| |
| dbp:c
| |
| dbp:casNumber
| |
| dbp:chembl
| |
| dbp:chemspiderid
| |
| dbp:dailymedid
| |
| dbp:drugbank
| |
| dbp:h
| |
| dbp:iupacName
| |
| dbp:kegg
| |
| dbp:legalEu
| |
| dbp:legalUs
| |
| dbp:medlineplus
| |
| dbp:n
| |
| dbp:o
| |
| dbp:pubchem
| |
| dbp:routesOfAdministration
| |
| dbp:smiles
|
- CCN1CC2=CCOC3=CC=CCO (en)
|
| dbp:stdinchi
| |
| dbp:stdinchikey
|
- FWCVZAQENIZVMY-UHFFFAOYSA-N (en)
|
| dbp:synonyms
| |
| dbp:tradename
| |
| dbp:unii
| |
| dbp:wikiPageUsesTemplate
| |
| dcterms:subject
| |
| rdf:type
| |
| rdfs:comment
|
- Voxelotor ist ein Arzneistoff zur Behandlung einer Blutarmut (hämolytische Anämie) aufgrund von Sichelzellkrankheit. Unter dem Handelsnamen Oxbryta (Hersteller: ) wurde er im November 2019 in den USA und im Februar 2022 in der EU zugelassen. Voxelotor ist oral anwendbar. (de)
- Вокселотор (Voxelotor, Оксбрита / Oxbryta) — лекарственный препарат для лечения серповидноклеточной анемии. В ноябре 2019 года Food and Drug Administration США в ускоренном режиме одобрило препарат компании . (ru)
- Voxelotor, sold under the brand name Oxbryta, is a medication used for the treatment of sickle cell disease. Developed by , voxelotor is the first hemoglobin oxygen-affinity modulator. Voxelotor has been shown to have disease-modifying potential by increasing hemoglobin levels and decreasing hemolysis indicators in sickle cell patients. It has a safe profile in sickle cell patients and healthy volunteers, without any dose-limiting toxicity. (en)
|
| rdfs:label
|
- Voxelotor (de)
- Вокселотор (ru)
- Voxelotor (en)
|
| owl:sameAs
| |
| prov:wasDerivedFrom
| |
| foaf:depiction
| |
| foaf:isPrimaryTopicOf
| |
| is dbo:wikiPageRedirects
of | |
| is dbo:wikiPageWikiLink
of | |
| is foaf:primaryTopic
of | |